![](https://danskbiotek.dk/wp-content/uploads/2020/04/ymabs-300x79.jpg)
Y-mAbs Announces Proposed Public Offering of Common Stock 16 February 2021
PRESS RELEASE NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company”... Read more
PRESS RELEASE NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company”... Read more
LINK Medical, the Northern European clinical research organization (CRO), and the Swedish women’s health... Read more
2cureX is pleased to announce that Kenneth Graabek Johansen has been appointed new CFO and will start... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical... Read more
2cureX is pleased to announce that Fernando Andreu has been appointed new CEO and will start latest on... Read more
DANISH BIO – DANSK BIOTEK conducted its first virtual members’ meeting ever on December 11 on the... Read more
ARTIKEL Antallet af private kliniske forsøg i Danmark står stille Trods flere års offentlig-privat... Read more
IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough... Read more
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more